4 female Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Dorit Donoviel of TRISH, Anu Pansare of gBETA, and Christine Galib and Courtney Cogdill of The Ion. Courtesy photos

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to four innovators across industries recently making headlines — from space tech to startup development organizations.

Dorit Donoviel, director of the Translational Research Institute for Space Health

NASA has renewed its support for Baylor College of Medicine's Translational Research Institute for Space Health. Libby Neder Photography

Baylor College of Medicine's Translational Research Institute for Space Health, known as TRISH, got the green light on a grant renewal from NASA, which will allow the organization to continue to conduct biomedical research geared at protecting astronauts in deep space through 2028. NASA opted to continue the partnership and now TRISH will receive additional funding of up to $134.6 million from 2022 to 2028.

"NASA has received outstanding value from our bold approach to sourcing and advancing space health research and technologies," institute director Dorit Donoviel, says in a statement. "We are proud to be NASA's partner in its human space exploration mission and to be supporting the research necessary to create new frontiers in healthcare that will benefit all humans." Click here to read more.

Anu Pansare, director of gBETA Houston

Anu Pansare has joined the local gBETA team. Photo via gbetastartups.com

Anu Pansare has a new gig. The Sugar Land-based consultant has over 20 years of experience working with the likes of Chevron, Schlumberger, and Accenture, as well as smaller startups. Pansare, who's also been involved with the Houston Angel Network, recently started as director of gBETA's Houston office.

As the main liaison between Houston and gener8tor's national network, Pansare will lead gBETA's third cohort — for which applications are open online — through its free 7-week program, which is designed to help participating companies gain early customer traction and develop key metrics that will make them more marketable for future investment. Click here to read more.

Christine Galib and Courtney Cogdill of The Ion

Christine Galib and Courtney Cogdill of The Ion join the Houston Innovators Podcast to discuss the four accelerator programs that are striving to advance Houston. Photos courtesy of The Ion

Courtney Cogdill, program director of the Accelerator Hub, and Christine Galib, senior director, at The Ion joined the Houston Innovators Podcast to discuss what all they are focused on across the business accelerator programs at the hub. Now more than ever, innovators are dedicating their careers to resilient technologies that can enhance the city's future. And this effort comes naturally to Houstonians, Galib says on the podcast.

"There is an ethos here that is one of roll up your sleeves, collaborate, and get to work. Get the work done, and have fun while you're doing it," she says on the show. "We all come together in a time of challenge, and we really show each other that we're not just individually resilient, we are collectively resilient."  Click here to read more and stream the episode.

Anu Pansare has joined the local gBETA team. Photo via gbetastartups.com

Early-stage accelerator names new Houston leader, opens applications for next cohort

now open

Houston's gBETA accelerator announced new leadership in conjunction with opening enrollment for its latest cohort this week.

The early-stage program, which is a part of Wisconsin-based gener8tor, has named Anu Pansare as its new director.

Pansare has spent the last 20 years at Sugar Land-based consulting firm Volyx and has also worked with big names like Chevron, Schlumberger, and Accenture, as well as smaller startups. She's also been involved with the Houston Angel Network. She will be replacing the accelerator's inaugural director Eléonore Cluzel in the position.

As the main liaison between Houston and gener8tor's national network, Pansare will lead gBETA's third cohort of early stage startups through its free 7-week program, which is designed to help participating companies gain early customer traction and develop key metrics that will make them more marketable for future investment.

"Downtown Launchpad is an inclusive ecosystem of tools, resources, and opportunities that help founders accelerate and scale their businesses to solve humankind's boldest challenges," says Robert Pieroni, director of economic development at Central Houston, in a press release. "The addition of Anu Pansare as gener8tor's new Houston director will strengthen our commitment to entrepreneurs in Houston and will help us evolve our strategy to better serve our founders, startups, partners, and our community."

Applications for the new cohort are open online until March 13.The zero-equity, no-fee program looks for locally based startups still in the early stage of business. Five companies will be selected.

The program is hosting a virtual webinar in partnership with SCORE Houston on March 1 to discuss the program and opportunities for interested startups. Event registration is free.

Houston's gBETA presence was launched thanks to a $1.25 million grant approved by the Downtown Redevelopment Authority in 2019 with support from Central Houston, the City of Houston, and Amegy Bank. The local team has an office at the Downtown Launchpad coworking space in the Amegy Bank Building on Main.

About a year into operations, gBETA has worked with 10 local startups in two cohorts across industries — from food tourism to sports technology, artificial intelligence for home buying to skincare and prescription solutions.

Pansare will be

holding virtual office hours for local entrepreneurs to provide insight and information about gBETA's Houston Spring 2021 program. More information on the program can be found at gBETA Houston's website or email Pansare directly at anu@gener8tor.com.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

     
  • $1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
  • $922 million for the University of Houston System
  • $167 million for Texas Southern University
  • $10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

     
  • Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
  • Created the Lake Houston Dredging and Maintenance District
  • Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.

View All Listings